Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02691299
Other study ID # 2015-013-00CH1
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date December 9, 2015
Est. completion date November 16, 2018

Study information

Verified date February 2019
Source Hutchison Medipharma Limited
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Fruquintinib/Placebo 5 mg, QD, orally administered under fasting conditions for 3 consecutive weeks followed by one-week off to evaluate the survival benefit of patients with advanced non-squamous NSCLC treated with Fruquintinib.


Description:

This is a randomized, double-blind, placebo-controlled, multi-center Phase III clinical trial in patients with advanced non-squamous non-small cell lung cancer (NSCLC) treated with Fruquintinib who failed 2 lines of systemic chemotherapy or with non-tolerable toxicities.

Approximately 521 subjects will be randomized to Fruquintinib group or placebo group at a ratio of 2:1. Patients in the two groups can receive supportive treatment.

Randomization will be stratified by EGFR gene status (mutant vs. wild type) and history of treatment by VEGF inhibitors (yes vs no) .

All subjects will receive study treatment in 4-week cycles: Fruquintinib/placebo for 3 consecutive weeks, and then one week off. Tumor assessment will be performed every 4 weeks in the first 2 cycles, and every 8 weeks since the 3rd cycle, until disease progression or death. Subsequent anti-neoplastic treatment and survival status will be followed up after disease progression.


Recruitment information / eligibility

Status Completed
Enrollment 527
Est. completion date November 16, 2018
Est. primary completion date September 21, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

1. Fully understand the study and sign the informed consent form voluntarily;

2. Histologically or cytologically diagnosed with local advanced and/or metastatic stage IIIB/IV non-squamous NSCLC;

3. Disease progressed or developed non-tolerable toxicity after 2 lines of systemic chemotherapy (not including TKI therapy); Notes: a. The first-line chemotherapy should be platinum-based doublets regimens; b. For each line of systemic therapy, at least one treatment cycle should be completed, and maintenance therapy using one of the doublets is considered as the same line of therapy; c. Previous adjuvant/neoadjuvant therapy is allowed. If disease progressed during the adjuvant/neoadjuvant therapy period or within 1 year after completion of the above treatment, it is considered that patient failed the first-line systemic chemotherapy;

4. Patients with EGFR genetic test negative; or positive with EGFR, test result but resistant or intolerable to related targeted therapies;

5. Patients with ALK test negative; or positive with ALK test result but resistant or intolerable to related targeted therapies;

6. Aged 18-75 years (inclusive);

7. Measurable disease (according to RECIST1.1);

8. ECOG Performance Status score 0-1;

9. Life expectancy >12 weeks.

Exclusion Criteria:

1. Patients who have participated in another clinical trial or received systemic anti-neoplastic therapy, radiotherapy or biotherapy within 3 weeks prior to administration of the study drug; or received EGFR-TKI treatment in the past 1 week.

2. Patients who have previously received therapy with VEGFR inhibitors;

3. Patients who have not recovered from toxicity caused by previous anti-neoplastic treatment (CTCAE > grade 1), or not completely recovered from previous surgery;

4. Patient with active brain metastasis (untreated with proper radiation therapy, showing clinical symptoms or symptom stable time less than 4 weeks, or indicated for symptomatic treatment for brain metastasis, etc.);

5. Patients with other primary malignancies within the past 5 years except basal cell carcinoma of skin or carcinoma in situ of cervix;

6. Patients with uncontrolled active infections, e.g. acute pneumonia, active hepatitis B or active hepatitis C, etc. (for patients with a history of hepatitis B, whether treated or not, HBV DNA =500copies or = 100IU / ml);

7. Patients with dysphagia or known drug malabsorption;

8. Patients active duodenal ulcer, ulcerative colitis, intestinal obstruction and other gastrointestinal diseases or other conditions that may lead to gastrointestinal bleeding or perforation according to the investigators' judgment; or with a history of intestinal perforation or intestinal fistula;

9. Patients fulfilling any of the following criteria shall be excluded:

1) Absolute neutrophil count (ANC) <1.5×109/L, platelet <100×109/L or hemoglobin <9 g/dL within 1 week prior to enrollment;

2) Serum total bilirubin > 1.5 × upper limit of normal (ULN), alanine transaminase and aspartate aminotransferase >2.5×ULN (according to reference range in each clinical study site); ALT and AST > 5×ULN in patients with liver metastasis;

3) Clinically significant electrolyte abnormality;

4) Blood creatinine > ULN and creatinine clearance <60 ml/min;

5) Urine protein 2+ or more, or urine protein quantification =1.0 g/24 h;

6) Activated partial thromboplastin time (APTT) or/and INR and prothrombin time (PT) > 1.5×ULN (according to reference range in each clinical study site);

10. Patients with uncontrolled hypertension, systolic blood pressure =140 mmHg and/or diastolic blood pressure =90 mmHg after symptomatic treatment;

11. Patients with left ventricular ejection fraction <50% (echocardiography) in heart function evaluation;

12. Patients with acute myocardial infarction, severe/unstable angina or coronary bypass surgery within 6 months prior to enrollment; cardiac insufficiency of NYHA II or above;

13. Patients who have a history of arterial thrombosis or deep venous thrombosis within 6 months prior to enrollment, history or evidence of thrombosis or bleeding tendency regardless of the severity within 2 months prior to enrollment; history of hemoptysis (i.e. coughing blood in bright red color or at least 1/2 teaspoon) within 2 weeks prior to enrollment;

14. Patients who have a history of stroke and/or transient ischemic attack within 12 months prior to enrollment;

15. Patients with skin wound, surgical site, wound site, severe mucosal ulcer or fracture without complete healing;

16. Pregnant or lactating women, or women of child bearing potential with positive pregnancy test result before the first dose;

17. Patients with child bearing potential who or whose sexual partners are not willing to take contraceptive measures;

18. Patients with any clinical or laboratory abnormalities unsuitable for participating in this clinical trial according to the investigator's judgment;

19. Patients with serious psychological or psychiatric disorders which may affect subject compliance in this clinical study;

20. Patients who are allergic to analogue of Fruquintinib and/or its inactive ingredients.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Fruquintinib
Fruquintinib is a capsule in the form of 5mg and 1mg, orally once daily. 3 weeks on/1 week off
Placebo
Placebo is a capsule in the form of 5mg and 1mg, orally once daily. 3 weeks on/1 week off

Locations

Country Name City State
China 307 Hospital of PLA Beijing Beijing
China Beijing Cancer Hospital Beijing Beijing
China Beijing Chest Hospital Beijing Beijing
China The First Hospital of Jilin University Changchun Jilin
China West China Hospital Chengdu Sichuan
China Guangdong General Hospital Guangzhou Guangdong
China The First Affiliated Hosptial of College of Medicine, Zhejiang University Hangzhou Zhejiang
China Linyi Tumor Hospital Linyi Shandong
China Nantong Tumor Hospital Nantong Jiangsu
China Shanghai Chest Hospital Shanghai Shanghai
China The Cancer Hospital of Fudan University Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Hutchison Medipharma Limited

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary overall survival (OS) Duration from randomization to death from any cause From the date of randomization until the date of death from any cause, Assessed up to 15 months
Secondary Objective Response Rate (ORR) Occurence of completed response or partial response after treatment, assessed by RECIST 1.1 From date of randomization until the date of first documented progression or the date of death from any cause, whichever came first, assessed up to 12 months
Secondary progression free survival (PFS) The duration from randomization to first documented progression or death from any cause, whichever came first, assessed by RECIST 1.1 From date of randomization until the date of first documented progression or the date of death from any cause, whichever came first, assessed up to 12 months
Secondary Disease Control Rate (DCR) Occurence of completed response, or partial response, or stable disease, assessed by RECIST 1.1 From date of randomization until the date of first documented progression or the date of death from any cause, whichever came first, assessed up to 12 months
Secondary duration of response (DOR) Duration from first documented completed response or partial response to first documented progression or death from any cause, whichever came first From date of randomization until the date of first documented progression or the date of death from any cause, whichever came first, assessed up to 12 months
Secondary safety and tolerability by incidence, severity and outcome of adverse events To evaluate the safety and tolerability in the two groups by incidence, severity and outcomes of AEs and categorized by severity in accordance with the NCI CTC AE Version 4.03 From randomization to 30 days after last dose, assessed up to 13 months
See also
  Status Clinical Trial Phase
Recruiting NCT05821933 - RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC Phase 1/Phase 2
Active, not recruiting NCT03269162 - Postoperative NSCLC Treated With Integrated Medicine Base on Circulating Tumor Cell Detection Phase 3
Recruiting NCT05002270 - JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation Phase 1/Phase 2
Recruiting NCT06315686 - The Dynamic Monitoring of Cerebrospinal Fluid ctDNA Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Recruiting NCT05466149 - Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Completed NCT03609918 - Comprehensive Analysis of Gene Mutation Profile in Chinese NSCLC Patients by Next-generation Sequencing
Recruiting NCT06043817 - First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Phase 1/Phase 2
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Recruiting NCT05078931 - A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients Phase 2
Not yet recruiting NCT05547737 - Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer
Not yet recruiting NCT05909137 - Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer
Withdrawn NCT05959473 - EGFR_IUO 3.20 Clinical Study Protocol N/A
Not yet recruiting NCT05005468 - A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC. Phase 2
Recruiting NCT01690390 - Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease Phase 2
Completed NCT01852578 - Cabazitaxel in Relapsed and Metastatic NSCLC Phase 2
Active, not recruiting NCT01460472 - Immunotherapy With Racotumomab in Advanced Lung Cancer Phase 3
Completed NCT00866970 - Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia Phase 2
Completed NCT00702975 - Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy Phase 2